Echocardiographic analysis revealed that MARCH5 overexpression markedly aggravated TAC‐induced cardiac hypertrophy, as demonstrated by an increase in LVAWd and a decrease in LVEF and LVFS compared to the AAV9‐vector‐TAC group, 4 weeks post‐TAC (Figure 4C and Figure S1A,B). This evidence concerns the gene MARCHF5 and cardiac hypertrophy.